Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cancer vaccine aims to stop leukemia from coming back

NCT ID NCT03059485

First seen Feb 01, 2026 · Last updated Apr 29, 2026 · Updated 10 times

Summary

This study tests a personalized vaccine made from a patient's own leukemia cells and immune cells. The goal is to train the immune system to recognize and destroy any remaining cancer cells after chemotherapy, helping to prevent the leukemia from returning. The trial involves 82 adults aged 55 and older with acute myeloid leukemia (AML) who are in remission. Half receive the vaccine, and half are simply observed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOGENOUS LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02214, United States

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin, 53792, United States

Conditions

Explore the condition pages connected to this study.